A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
An Open-label Trial of Risperidone Long-acting Injectable in the Treatment of Subjects With Recent Onset Psychosis
An Open-label Trial of Risperidone Long-acting Injectable in the Treatment of Subjects With Recent Onset Psychosis
Sponsor study identifier
Secondary identifiers
OTHER · Janssen Pharmaceutica N.V., Belgium
interventional
50
0 countries
N/A
Study Start
February 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
December 2006
Actual (reported)The purpose of the study is to assess the effectiveness and safety of long-acting injectable risperidone in the treatment of patients in the early stage of psychosis
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2004
Date type not reportedThis date has not been verified as actual or estimated.
September 13, 2005
Actual (reported)September 22, 2005
Actual (reported)December 2006
Actual (reported)Change in Positive and Negative Syndrome Scale (PANSS) from baseline to end of study
Time from initiation of treatment to relapse; changes in Calgary Depression Scale for Schizophrenia (CDSS), Clinical Global Impression (CGI) scales, Extrapyramidal Symptom Rating Scale (ESRS) at intervals throughout study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Janssen Pharmaceutica N.V. Clinical Trial
Janssen Pharmaceutica N.V.
50 participants (actual enrollment reported by the registry).
First Submitted
September 13, 2005
First Posted
September 22, 2005
Study Start
February 2004
Date type not reportedThis date has not been verified as actual or estimated.
Investigate Risperidone for the Treatment of Schizophrenia in Adolescents
Contact the study team to confirm eligibility.
Study Completion
December 2006
Actual (reported)Last Updated
March 25, 2013
Record last verified: 2013-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: